CL2022001706A1 - Anticuerpos o proteínas de unión a cd163. - Google Patents

Anticuerpos o proteínas de unión a cd163.

Info

Publication number
CL2022001706A1
CL2022001706A1 CL2022001706A CL2022001706A CL2022001706A1 CL 2022001706 A1 CL2022001706 A1 CL 2022001706A1 CL 2022001706 A CL2022001706 A CL 2022001706A CL 2022001706 A CL2022001706 A CL 2022001706A CL 2022001706 A1 CL2022001706 A1 CL 2022001706A1
Authority
CL
Chile
Prior art keywords
porcine
antigen
binds
amino acid
binding domain
Prior art date
Application number
CL2022001706A
Other languages
English (en)
Spanish (es)
Inventor
Charles Owen
Hafid Abdelaali Benchaoui
Christine Tait-Burkard
Original Assignee
Eco Animal Health Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eco Animal Health Ltd filed Critical Eco Animal Health Ltd
Publication of CL2022001706A1 publication Critical patent/CL2022001706A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CL2022001706A 2019-12-24 2022-06-20 Anticuerpos o proteínas de unión a cd163. CL2022001706A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1919294.7A GB201919294D0 (en) 2019-12-24 2019-12-24 Antibodies or binding proteins

Publications (1)

Publication Number Publication Date
CL2022001706A1 true CL2022001706A1 (es) 2023-05-26

Family

ID=69322779

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022001706A CL2022001706A1 (es) 2019-12-24 2022-06-20 Anticuerpos o proteínas de unión a cd163.

Country Status (13)

Country Link
US (1) US20230203185A1 (enExample)
EP (1) EP4081542A1 (enExample)
JP (1) JP7702952B2 (enExample)
KR (1) KR20220119147A (enExample)
CN (1) CN121873247A (enExample)
BR (1) BR112022012362A2 (enExample)
CL (1) CL2022001706A1 (enExample)
CO (1) CO2022010294A2 (enExample)
DO (2) DOP2022000136A (enExample)
GB (1) GB201919294D0 (enExample)
MX (1) MX2022007957A (enExample)
PE (1) PE20230384A1 (enExample)
WO (1) WO2021130502A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12098400B2 (en) * 2022-07-08 2024-09-24 Novo Nordisk A/S Highly potent ISVD compounds capable of substituting for FVIII(A)
GB202214979D0 (en) * 2022-10-11 2022-11-23 Eco Animal Health Ltd Binding protein
EP4655324A1 (en) * 2023-01-27 2025-12-03 Vib Vzw Cd163-binding conjugates
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
CN119569865B (zh) * 2024-12-20 2025-10-10 西北农林科技大学 一种防治猪繁殖与呼吸障碍综合征病毒感染的混合制剂及其制备方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS65691B1 (sr) 2015-08-06 2024-07-31 Univ Missouri Svinja i ćelije rezistentne na virus reproduktivnog i respiratornog sindroma svinja (prrsv) koje imaju modifikovane cd163 gene
US11160260B2 (en) * 2018-04-17 2021-11-02 The Curators Of The University Of Missouri Methods for protecting porcine fetuses from infection with porcine reproductive and respiratory syndrome virus (PRRSV)

Also Published As

Publication number Publication date
US20230203185A1 (en) 2023-06-29
WO2021130502A1 (en) 2021-07-01
KR20220119147A (ko) 2022-08-26
CA3162664A1 (en) 2021-07-01
JP2023508674A (ja) 2023-03-03
CN115151569A (zh) 2022-10-04
GB201919294D0 (en) 2020-02-05
BR112022012362A2 (pt) 2022-09-06
JP7702952B2 (ja) 2025-07-04
DOP2022000136A (es) 2022-11-30
DOP2025000290A (es) 2026-02-26
CO2022010294A2 (es) 2022-10-31
EP4081542A1 (en) 2022-11-02
MX2022007957A (es) 2022-10-07
PE20230384A1 (es) 2023-03-06
CN121873247A (zh) 2026-04-17

Similar Documents

Publication Publication Date Title
CL2022001706A1 (es) Anticuerpos o proteínas de unión a cd163.
CR20210199A (es) Moléculas de unión a antígeno capaces de unirse al cúmulo de diferenciación 3 (cd3) y al cúmulo de diferenciación 137 (cd137) pero no simultáneamente
CR20200579A (es) Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
AR109882A1 (es) Anticuerpos monoclonales neutralizantes anti-tl1a
IL299221A (en) Cd3 binding antibodies
HRP20241381T1 (hr) Nova anti-pd-1 protutijela
AR106184A1 (es) Proteínas de unión a pd-1 y sus métodos de uso
PE20251579A1 (es) Anticuerpos especificos para cd70 y sus usos
PE20120475A1 (es) Anticuerpos especificos para dkk-1
CO2023009615A2 (es) Anticuerpos multiespecíficos que tienen especificidad para il-4r e il-31
PE20191031A1 (es) ANTICUERPOS ANTI-C1s Y METODOS DE USO DE LOS MISMOS
NI201800113A (es) Anticuerpos anti-basigin humanizados y uso de los mismos.
CO2021014153A2 (es) Anticuerpo monoclonal que se une específicamente a gitr
PE20230839A1 (es) Agentes de union a lair-1 y metodos para su uso
EA201792329A1 (ru) Способ мономеризации рекомбинантных молекул антител
PE20230306A1 (es) Anticuerpos que se dirigen a un complejo que comprende hla-i no clasico y neoantigeno y sus metodos de uso
IL250289B2 (en) Antibodies against angiopoietin-like 4 and methods of use
WO2020257789A3 (en) Anti-tim-3 antibodies
AR087485A1 (es) Anticuerpos de union a fosforilcolina (pc) y/o conjugados de pc
MX2022006728A (es) Metodos y combinaciones para el tratamiento del cancer utilizando anticuerpos inhibidores de puntos de control inmunitario.
BR112022011323A2 (pt) Anticorpo biespecífico anti-antígeno de maturação de célula b (bcma)/anti-4-1bb ou um fragmento de ligação ao antígeno do mesmo, e composição farmacêutica para prevenção ou tratamento de uma doença relacionada ao bcma, 4-1bb ou ambos
EA201991510A1 (ru) Каркасы антител для снижения агрегирования полиспецифических антител
BR112022006364A2 (pt) Anticorpo híbrido
AR126971A1 (es) Composiciones y métodos para tratar el síndrome de qt largo
AR130641A1 (es) Anticuerpos anti-cd28